StockData

biote vs Glass House Brands

BTMD and GLAS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BTMD and GLAS compare

biote grew revenue faster over the last twelve months (−8.6% versus −9.4% for Glass House Brands).

biote keeps more of each dollar of sales as profit, with a net margin of −1.1% compared with −16.3% at Glass House Brands.

Glass House Brands scores higher on the StockData Score (5 against 4 for biote), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBTMDGLAS
Size and price
Market cap$38.3M–
Share price$1.06$1.27
Change, 1 year−59.7%−83.1%
Change, 5 years−89.1%−72.1%
Beta (5Y)0.510.67
Employees223472
StockData Score
Total score45 (better)
Valuation score1 (better)0
Growth score01 (better)
Performance score23 (better)
Health score11
Dividend score00
Valuation
P/S0.2×–
EV/EBITDA12.2×–
P/FCF5.2×–
FCF yield19.4%–
Growth
Revenue growth (TTM)−8.6% (better)−9.4%
Revenue growth, 5Y average–30.4%
Net income growth (TTM)−107% (better)−5815%
EPS growth (TTM)−114%–
Profitability
Gross margin67.5% (better)42.3%
Operating margin5.0% (better)−9.1%
Net margin−1.1% (better)−16.3%
FCF margin4.1% (better)−8.6%
Return on equity–−31.2%
Return on invested capital18.5% (better)−9.9%
Financial health
Debt / equity–0.93
Net debt / EBITDA8.62–
Interest coverage–−2.3×
Current ratio1.371.78 (better)
Altman Z-score1.65–
Piotroski F-score6 (better)3
Dividends and buybacks
Buyback yield18.9%–
Shareholder yield18.9%–
Ownership
Held by institutions36.6%24.9%
Held by insiders23.3%0.04%
Insider net buying, 12 months$202K (better)−$354K
Short interest, % of float3.1%0.82%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.